BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24474818)

  • 1. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
    Eba J; Kenmotsu H; Tsuboi M; Niho S; Katayama H; Shibata T; Watanabe S; Yamamoto N; Tamura T; Asamura H; ;
    Jpn J Clin Oncol; 2014 Apr; 44(4):379-82. PubMed ID: 24474818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
    Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
    Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206.
    Kenmotsu H; Niho S; Tsuboi M; Wakabayashi M; Ishii G; Nakagawa K; Daga H; Tanaka H; Saito H; Aokage K; Takahashi T; Menju T; Kasai T; Yoshino I; Minato K; Okada M; Eba J; Asamura H; Ohe Y; Watanabe SI
    J Clin Oncol; 2020 Dec; 38(36):4292-4301. PubMed ID: 33136471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
    Eba J; Shimokawa T; Nakamura K; Shibata T; Misumi Y; Okamoto H; Yamamoto N; Ohe Y;
    Jpn J Clin Oncol; 2015 Jan; 45(1):115-8. PubMed ID: 25332420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
    Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
    Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
    Tsuchiya R; Suzuki K; Ichinose Y; Watanabe Y; Yasumitsu T; Ishizuka N; Kato H
    J Thorac Cardiovasc Surg; 2005 May; 129(5):977-83. PubMed ID: 15867769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
    Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
    J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
    Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
    Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
    Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
    J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study).
    Kataoka K; Tsushima T; Mizusawa J; Hironaka S; Tsubosa Y; Kii T; Shibuya Y; Chin K; Katayama H; Kato K; Fukuda H; Kitagawa Y;
    Jpn J Clin Oncol; 2015 May; 45(5):494-8. PubMed ID: 25646357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
    Mizugaki H; Fujiwara Y; Yamamoto N; Yagishita S; Kitazono S; Tanaka A; Horinouchi H; Kanda S; Nokihara H; Tsuta K; Asamura H; Tamura T
    Jpn J Clin Oncol; 2014 Sep; 44(9):835-40. PubMed ID: 25097183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma.
    Iyoda A; Hiroshima K; Moriya Y; Iwadate Y; Takiguchi Y; Uno T; Nakatani Y; Yoshino I
    J Thorac Cardiovasc Surg; 2009 Aug; 138(2):446-53. PubMed ID: 19619794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
    Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment strategy for neuroendocrine carcinoma of the lung].
    Kawase A; Nagai K
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1619-22. PubMed ID: 19838019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
    Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
    Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma.
    Iyoda A; Hiroshima K; Moriya Y; Takiguchi Y; Sekine Y; Shibuya K; Iizasa T; Kimura H; Nakatani Y; Fujisawa T
    Ann Thorac Surg; 2006 Nov; 82(5):1802-7. PubMed ID: 17062251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
    Keller SM; Adak S; Wagner H; Herskovic A; Komaki R; Brooks BJ; Perry MC; Livingston RB; Johnson DH
    N Engl J Med; 2000 Oct; 343(17):1217-22. PubMed ID: 11071672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
    Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
    Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.